Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Advances in Diagnosis and Multidisciplinary Management of Oropharyngeal Squamous Cell Carcinoma: State of the Art.

Parvathaneni U, Lavertu P, Gibson MK, Glastonbury CM.

Radiographics. 2019 Oct 11:190007. doi: 10.1148/rg.2019190007. [Epub ahead of print]

PMID:
31603733
2.

Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205).

Gibson MK, Catalano P, Kleinberg LR, Staley CA 3rd, Montgomery EA, Jimeno A, Song WF, Mulcahy MF, Leichman LP, Benson AB 3rd.

Oncologist. 2019 Jun 21. pii: theoncologist.2018-0750. doi: 10.1634/theoncologist.2018-0750. [Epub ahead of print]

PMID:
31227647
3.

Adaptive Strategies of the Candidate Probiotic E. coli Nissle in the Mammalian Gut.

Crook N, Ferreiro A, Gasparrini AJ, Pesesky MW, Gibson MK, Wang B, Sun X, Condiotte Z, Dobrowolski S, Peterson D, Dantas G.

Cell Host Microbe. 2019 Apr 10;25(4):499-512.e8. doi: 10.1016/j.chom.2019.02.005. Epub 2019 Mar 26.

PMID:
30926240
4.

Publisher Correction: Shared strategies for β-lactam catabolism in the soil microbiome.

Crofts TS, Wang B, Spivak A, Gianoulis TA, Forsberg KJ, Gibson MK, Johnsky LA, Broomall SM, Rosenzweig CN, Skowronski EW, Gibbons HS, Sommer MOA, Dantas G.

Nat Chem Biol. 2019 Feb;15(2):206. doi: 10.1038/s41589-018-0208-z.

PMID:
30591731
5.

Characterization of Wild and Captive Baboon Gut Microbiota and Their Antibiotic Resistomes.

Tsukayama P, Boolchandani M, Patel S, Pehrsson EC, Gibson MK, Chiou KL, Jolly CJ, Rogers J, Phillips-Conroy JE, Dantas G.

mSystems. 2018 Jun 26;3(3). pii: e00016-18. doi: 10.1128/mSystems.00016-18. eCollection 2018 May-Jun.

6.

Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.

Kang KH, Grubb W, Sawlani K, Gibson MK, Hoimes CJ, Rogers LR, Lavertu P, Yao M.

Am J Otolaryngol. 2018 Sep - Oct;39(5):642-645. doi: 10.1016/j.amjoto.2018.06.003. Epub 2018 Jun 5. Review.

PMID:
29903623
7.

Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma.

Yoon H, Karapetyan L, Choudhary A, Kosozi R, Bali GS, Zaidi AH, Atasoy A, Forastiere AA, Gibson MK.

Oncologist. 2018 Sep;23(9):1004-e102. doi: 10.1634/theoncologist.2017-0657. Epub 2018 May 16.

8.

Shared strategies for β-lactam catabolism in the soil microbiome.

Crofts TS, Wang B, Spivak A, Gianoulis TA, Forsberg KJ, Gibson MK, Johnsky LA, Broomall SM, Rosenzweig CN, Skowronski EW, Gibbons HS, Sommer MOA, Dantas G.

Nat Chem Biol. 2018 Jun;14(6):556-564. doi: 10.1038/s41589-018-0052-1. Epub 2018 Apr 30. Erratum in: Nat Chem Biol. 2019 Feb;15(2):206.

9.

Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma.

Das S, Gibson MK.

Oncol Hematol Rev. 2018;14(2):82-88. doi: 10.17925/OHR.2018.14.2.82. Epub 2018 Nov 27.

10.

Draft Genome Sequences of Three β-Lactam-Catabolizing Soil Proteobacteria.

Crofts TS, Wang B, Spivak A, Gianoulis TA, Forsberg KJ, Gibson MK, Johnsky LA, Broomall SM, Rosenzweig CN, Skowronski EW, Gibbons HS, Sommer MOA, Dantas G.

Genome Announc. 2017 Aug 10;5(32). pii: e00653-17. doi: 10.1128/genomeA.00653-17.

11.

IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.

Stabile LP, Egloff AM, Gibson MK, Gooding WE, Ohr J, Zhou P, Rothenberger NJ, Wang L, Geiger JL, Flaherty JT, Grandis JR, Bauman JE.

Oral Oncol. 2017 Jun;69:38-45. doi: 10.1016/j.oraloncology.2017.03.011. Epub 2017 Apr 9.

12.

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R.

J Clin Oncol. 2017 May 10;35(14):1542-1549. doi: 10.1200/JCO.2016.70.1524. Epub 2017 Mar 22.

13.

Cardiovascular risk and prevention in patients with head and neck cancer treated with radiotherapy.

Okoye CC, Bucher J, Tatsuoka C, Parikh SA, Oliveira GH, Gibson MK, Machtay M, Yao M, Zender CA, Dorth JA.

Head Neck. 2017 Mar;39(3):527-532. doi: 10.1002/hed.24646. Epub 2016 Dec 29.

14.

Developmental dynamics of the preterm infant gut microbiota and antibiotic resistome.

Gibson MK, Wang B, Ahmadi S, Burnham CA, Tarr PI, Warner BB, Dantas G.

Nat Microbiol. 2016 Mar 7;1:16024. doi: 10.1038/nmicrobiol.2016.24.

15.

Antibiotic perturbation of the preterm infant gut microbiome and resistome.

Gasparrini AJ, Crofts TS, Gibson MK, Tarr PI, Warner BB, Dantas G.

Gut Microbes. 2016 Sep 2;7(5):443-9. doi: 10.1080/19490976.2016.1218584. Epub 2016 Jul 29. Review.

16.

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.

Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, Martin D, Gutkind JS, Hedberg ML, Grandis JR, Argiris A.

Head Neck. 2016 Dec;38(12):1759-1764. doi: 10.1002/hed.24501. Epub 2016 May 27.

PMID:
27232378
17.

Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.

Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulou M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, Chiosea SI, Branstetter B, Ferris RL.

Ann Oncol. 2016 Aug;27(8):1594-600. doi: 10.1093/annonc/mdw204. Epub 2016 May 13.

18.

High-Specificity Targeted Functional Profiling in Microbial Communities with ShortBRED.

Kaminski J, Gibson MK, Franzosa EA, Segata N, Dantas G, Huttenhower C.

PLoS Comput Biol. 2015 Dec 18;11(12):e1004557. doi: 10.1371/journal.pcbi.1004557. eCollection 2015 Dec.

19.

A Model Based on Pathologic Features of Superficial Esophageal Adenocarcinoma Complements Clinical Node Staging in Determining Risk of Metastasis to Lymph Nodes.

Davison JM, Landau MS, Luketich JD, McGrath KM, Foxwell TJ, Landsittel DP, Gibson MK, Nason KS.

Clin Gastroenterol Hepatol. 2016 Mar;14(3):369-377.e3. doi: 10.1016/j.cgh.2015.10.020. Epub 2015 Oct 26.

20.

Antibiotics and the developing infant gut microbiota and resistome.

Gibson MK, Crofts TS, Dantas G.

Curr Opin Microbiol. 2015 Oct;27:51-6. doi: 10.1016/j.mib.2015.07.007. Epub 2015 Aug 1. Review.

21.

Erratum: Gut resistome development in healthy twin pairs in the first year of life.

Moore AM, Ahmadi S, Patel S, Gibson MK, Wang B, Ndao IM, Deych E, Shannon W, Tarr PI, Warner BB, Dantas G.

Microbiome. 2015 Jul 23;3:29. doi: 10.1186/s40168-015-0095-4. eCollection 2015.

22.

The revised American Joint Committee on Cancer staging system (7th edition) improves prognostic stratification after minimally invasive esophagectomy for esophagogastric adenocarcinoma.

Zahoor H, Luketich JD, Weksler B, Winger DG, Christie NA, Levy RM, Gibson MK, Davison JM, Nason KS.

Am J Surg. 2015 Oct;210(4):610-7. doi: 10.1016/j.amjsurg.2015.05.010. Epub 2015 Jun 26.

23.

Gut resistome development in healthy twin pairs in the first year of life.

Moore AM, Ahmadi S, Patel S, Gibson MK, Wang B, Ndao MI, Deych E, Shannon W, Tarr PI, Warner BB, Dantas G.

Microbiome. 2015 Jun 25;3:27. doi: 10.1186/s40168-015-0090-9. eCollection 2015. Erratum in: Microbiome. 2015;3:29.

24.

A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.

Vargo JA, Ferris RL, Ohr J, Clump DA, Davis KS, Duvvuri U, Kim S, Johnson JT, Bauman JE, Gibson MK, Branstetter BF, Heron DE.

Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):480-8. doi: 10.1016/j.ijrobp.2014.11.023. Epub 2015 Jan 30.

PMID:
25680594
25.

A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma.

Zahoor H, Luketich JD, Levy RM, Awais O, Winger DG, Gibson MK, Nason KS.

J Thorac Cardiovasc Surg. 2015 Feb;149(2):538-47. doi: 10.1016/j.jtcvs.2014.10.044. Epub 2014 Oct 14.

26.

Longitudinal analysis of microbial interaction between humans and the indoor environment.

Lax S, Smith DP, Hampton-Marcell J, Owens SM, Handley KM, Scott NM, Gibbons SM, Larsen P, Shogan BD, Weiss S, Metcalf JL, Ursell LK, Vázquez-Baeza Y, Van Treuren W, Hasan NA, Gibson MK, Colwell R, Dantas G, Knight R, Gilbert JA.

Science. 2014 Aug 29;345(6200):1048-52. doi: 10.1126/science.1254529.

27.

Improved annotation of antibiotic resistance determinants reveals microbial resistomes cluster by ecology.

Gibson MK, Forsberg KJ, Dantas G.

ISME J. 2015 Jan;9(1):207-16. doi: 10.1038/ismej.2014.106. Epub 2014 Jul 8.

28.

The yin and yang of bacterial resilience in the human gut microbiota.

Gibson MK, Pesesky MW, Dantas G.

J Mol Biol. 2014 Nov 25;426(23):3866-76. doi: 10.1016/j.jmb.2014.05.029. Epub 2014 Jun 6. Review.

29.

Bacterial phylogeny structures soil resistomes across habitats.

Forsberg KJ, Patel S, Gibson MK, Lauber CL, Knight R, Fierer N, Dantas G.

Nature. 2014 May 29;509(7502):612-6. doi: 10.1038/nature13377. Epub 2014 May 21.

30.

A rare case of malignant glomus tumor of the esophagus.

Bali GS, Hartman DJ, Haight JB, Gibson MK.

Case Rep Oncol Med. 2013;2013:287078. doi: 10.1155/2013/287078. Epub 2013 Dec 17.

31.

MUC2 expression is an adverse prognostic factor in superficial gastroesophageal adenocarcinomas.

Davison JM, Ellis ST, Foxwell TJ, Luketich JD, Gibson MK, Kuan SF, Nason KS.

Hum Pathol. 2014 Mar;45(3):540-8. doi: 10.1016/j.humpath.2013.10.020. Epub 2013 Oct 30.

32.

Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium.

Malhotra U, Zaidi AH, Kosovec JE, Kasi PM, Komatsu Y, Rotoloni CL, Davison JM, R C, Irvin, Hoppo T, Nason KS, Kelly LA, Gibson MK, Jobe BA.

PLoS One. 2013 Nov 4;8(11):e78343. doi: 10.1371/journal.pone.0078343. eCollection 2013.

33.

Barrett's esophagus: cancer and molecular biology.

Gibson MK, Dhaliwal AS, Clemons NJ, Phillips WA, Dvorak K, Tong D, Law S, Pirchi ED, Räsänen J, Krasna MJ, Parikh K, Krishnadath KK, Chen Y, Griffiths L, Colleypriest BJ, Farrant JM, Tosh D, Das KM, Bajpai M.

Ann N Y Acad Sci. 2013 Oct;1300:296-314. doi: 10.1111/nyas.12252. Review.

PMID:
24117650
34.

Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.

Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ, Bahary N.

J Surg Oncol. 2013 Sep;108(4):236-41. doi: 10.1002/jso.23392.

35.

Novel resistance functions uncovered using functional metagenomic investigations of resistance reservoirs.

Pehrsson EC, Forsberg KJ, Gibson MK, Ahmadi S, Dantas G.

Front Microbiol. 2013 Jun 7;4:145. doi: 10.3389/fmicb.2013.00145. eCollection 2013.

36.

Oesophageal carcinoma.

Pennathur A, Gibson MK, Jobe BA, Luketich JD.

Lancet. 2013 Feb 2;381(9864):400-12. doi: 10.1016/S0140-6736(12)60643-6. Review.

37.

Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease.

Gibson MK, Zaidi AH, Davison JM, Sanz AF, Hough B, Komatsu Y, Kosovec JE, Bhatt A, Malhotra U, Foxwell T, Rotoloni CL, Hoppo T, Jobe BA.

Ann Surg. 2013 Jul;258(1):82-8. doi: 10.1097/SLA.0b013e318270500d.

PMID:
23108119
38.

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR Jr, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S.

Ann Oncol. 2013 Jan;24(1):220-5. doi: 10.1093/annonc/mds245. Epub 2012 Aug 16.

39.

The role of cetuximab in the management of head and neck cancers.

Kabolizadeh P, Kubicek GJ, Heron DE, Ferris RL, Gibson MK.

Expert Opin Biol Ther. 2012 Apr;12(4):517-28. doi: 10.1517/14712598.2012.667397. Review.

PMID:
22413826
40.

Retrospective review of patients with locally advanced esophageal cancer treated at the University of Pittsburgh.

Defoe SG, Pennathur A, Flickinger JC, Heron DE, Gibson MK, Luketich JD, Greenberger JS.

Am J Clin Oncol. 2011 Dec;34(6):587-92. doi: 10.1097/COC.0b013e3181f942af.

PMID:
22101387
41.

Barrett's esophagus and animal models.

Macke RA, Nason KS, Mukaisho K, Hattori T, Fujimura T, Sasaki S, Oyama K, Miyashita T, Ohta T, Miwa K, Gibson MK, Zaidi A, Malhotra U, Atasoy A, Foxwell T, Jobe B.

Ann N Y Acad Sci. 2011 Sep;1232:392-400. doi: 10.1111/j.1749-6632.2011.06061.x.

42.

Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group.

Yoon HH, Catalano PJ, Murphy KM, Skaar TC, Philips S, Powell M, Montgomery EA, Hafez MJ, Offer SM, Liu G, Meltzer SJ, Wu X, Forastiere AA, Benson AB, Kleinberg LR, Gibson MK.

BMC Cancer. 2011 May 17;11:176. doi: 10.1186/1471-2407-11-176.

43.

Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.

Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE.

Ann Oncol. 2011 Nov;22(11):2482-8. doi: 10.1093/annonc/mdr002. Epub 2011 Mar 1.

44.

Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group.

Yoon HH, Catalano P, Gibson MK, Skaar TC, Philips S, Montgomery EA, Hafez MJ, Powell M, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Murphy KM.

Cancer Chemother Pharmacol. 2011 Oct;68(4):863-70. doi: 10.1007/s00280-011-1556-5. Epub 2011 Feb 1.

45.

Targeted therapy: an evolving concept in esophageal adenocarcinoma.

Gibson MK, Malhotra U.

Oncology (Williston Park). 2010 Nov 15;24(12):1143, 1146, 1148. No abstract available.

46.

Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer.

Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, Branstetter BF, Posluszny DM, Wang L, Seethala RR, Dacic S, Gooding W, Grandis JR, Johnson JT, Ferris RL.

J Clin Oncol. 2010 Dec 20;28(36):5294-300. doi: 10.1200/JCO.2010.30.6423. Epub 2010 Nov 15.

47.

Rabeprazole impedes the development of reflux-induced esophageal cancer in a surgical rat model.

Miyashita T, Shah FA, Marti GP, Wang J, Bonde P, Gibson MK, Ohta T, Montgomery EA, Duncan M, Harmon JW.

Dig Dis Sci. 2011 May;56(5):1309-14. doi: 10.1007/s10620-010-1465-1. Epub 2010 Oct 30.

PMID:
21053077
48.

The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.

Rwigema JC, Heron DE, Ferris RL, Andrade RS, Gibson MK, Yang Y, Ozhasoglu C, Argiris AE, Grandis JR, Burton SA.

Am J Clin Oncol. 2011 Aug;34(4):372-9. doi: 10.1097/COC.0b013e3181e84dc0.

49.

Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study.

Heron DE, Rwigema JC, Gibson MK, Burton SA, Quinn AE, Ferris RL.

Am J Clin Oncol. 2011 Apr;34(2):165-72. doi: 10.1097/COC.0b013e3181dbb73e.

PMID:
20686406
50.

Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy.

Passero VA, Branstetter BF, Shuai Y, Heron DE, Gibson MK, Lai SY, Kim SW, Grandis JR, Ferris RL, Johnson JT, Argiris A.

Ann Oncol. 2010 Nov;21(11):2278-83. doi: 10.1093/annonc/mdq226. Epub 2010 Apr 29.

Supplemental Content

Loading ...
Support Center